微分的影响glucagon-like peptide-1受体受体激动剂对心率。

文章的细节

引用

复制到剪贴板

洛伦兹米,劳森F,欧文斯D, Raccah D, Roy-Duval C,莱曼,Perfetti R,金发L

微分的影响glucagon-like peptide-1受体受体激动剂对心率。

Cardiovasc Diabetol。2017年1月13日,16 (1):6。doi: 10.1186 / s12933 - 016 - 0490 - 6。

PubMed ID

28086882 (在PubMed

]

文摘

虽然glucagon-like peptide-1受体受体激动剂(GLP-1 RAs)已知增加心率(HR),这是不够认识到各种受体激动剂和之间的变化很大程度是影响评估方法。我们回顾从24小时发布数据时均在健康个体人力资源监控和主题2型糖尿病(T2DM)病人体内治疗与短效GLP-1 RAs, lixisenatide或exenatide或长效GLP-1 RAs, exenatide守护神,liraglutide, albiglutide或dulaglutide (N = 1112;积极治疗武器)。人力资源效应中观察到的两个独立的肉搏战试验lixisenatide和liraglutide (N = 202;积极治疗武器)也进行了综述。短效GLP-1 RAs, exenatide和lixisenatide与瞬态(1 - 12 h)的意思是安慰剂,baseline-adjusted 24小时人力资源增加每分钟1 - 3次(bpm)。相反,长效glp - 1在意味着RAs与更加明显增加24小时人力资源;与最高liraglutide和albiglutide 6 - 10 bpm相比dulaglutide和exenatide 3 - 4 bpm的守护神。liraglutide和dulaglutide,人力资源增加记录在一天和夜晚。在两个一对一的比较,一个小,瞬态意味着增加人力资源从基线与lixisenatide观察; liraglutide induced a substantially greater increase that remained significantly elevated over 24 h. The underlying mechanism for increased HR remains to be elucidated; however, it could be related to a direct effect at the sinus node and/or stimulation of the sympathetic nervous system, with this effect related to the duration of action of the respective GLP-1 RAs. In conclusion, this review indicates that the effects on HR differ within the class of GLP-1 RAs: short-acting GLP-1 RAs are associated with a modest and transient HR increase before returning to baseline levels, while some long-acting GLP-1 RAs are associated with a more pronounced and sustained increase during the day and night. Findings from recently completed trials indicate that a GLP-1 RA-induced increase in HR, regardless of magnitude, does not present an increased cardiovascular risk for subjects with T2DM, although a pronounced increase in HR may be associated with adverse clinical outcomes in those with advanced heart failure.

DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Albiglutide	Glucagon-like肽受体1	蛋白质	人类	是的	受体激动剂	细节
Dulaglutide	Glucagon-like肽受体1	蛋白质	人类	是的	受体激动剂	细节
Exenatide	Glucagon-like肽受体1	蛋白质	人类	是的	受体激动剂	细节
Lixisenatide	Glucagon-like肽受体1	蛋白质	人类	是的	受体激动剂	细节